FDA Invites Patients to Public Meeting on Functional Gastrointestinal (GI) Disorders April 2015

The Food and Drug Administration (FDA), invites patients to an upcoming public meeting on Functional Gastrointestinal (GI) Disorders to be held May 11, 2015 from 1pm–5pm (EDT) at the FDA Campus in Silver Spring, Maryland.

The purpose of the meeting is to gather patients’ perspectives on symptoms and daily impacts that matter most to them, and to discuss available approaches for treating functional GI disorders. FDA is particularly interested in obtaining patient feedback regarding impact on daily life and patients’ views on patient experiences with irritable bowel syndrome, gastroparesis, chronic persistent symptomatic gastroesophageal reflux despite standard therapeutic interventions, and chronic idiopathic constipation.

This meeting is an exciting opportunity for patients to bring their voice to FDA and the drug development process.

I encourage you to participate either in-person or through the live webcast.  FDA needs your help to make this meeting a success.

 Registration: www.pfddfunctionalgidisorders.eventbrite.com.

Meeting website: Public Meeting on Functional GI Disorders Patient-Focused Drug Development

Background: Watching these webinars on FDA and Patient-Focused Drug Development in advance may be helpful in preparing for the meeting.

If you have any questions, please feel free to contact us at PatientFocused@fda.hhs.gov.

 

Douglas A. Drossman, MD